Gastrointestinal Cancer | Norton Healthcare

Indication: Gastrointestinal Cancer

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib

Sub-indication: Advanced Gastrointestinal Stromal Tumors after Failure of Imatinib

Line of Therapy: Second Line

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Deciphera Pharmaceuticals, LLC

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.